Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Imagion Biosystems Ltd. ( (AU:IBX) ) is now available.
Imagion Biosystems has issued 3,048,484 new fully paid ordinary shares at a deemed price of 2.5 cents each following the conversion of 76,212 convertible notes held under its agreement with Mercer Street Global Opportunity Fund, LLC, leaving Mercer with a remaining balance of 2,750,000 convertible notes. In conjunction with the cleansing notice provided under Section 708A of the Corporations Act, the board reiterated that it expects to lodge its IND submission for the HER2+ Phase 2 clinical trial with the US FDA in the near term, signalling ongoing progress in its clinical development pipeline while maintaining compliance with continuous disclosure obligations.
The most recent analyst rating on (AU:IBX) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on Imagion Biosystems Ltd. stock, see the AU:IBX Stock Forecast page.
More about Imagion Biosystems Ltd.
Imagion Biosystems Limited is an Australian medical technology company developing non-radioactive, precision diagnostic molecular imaging solutions for earlier and more specific detection of cancer and other diseases. Using its proprietary MagSense® technology, which combines biotechnology and nanotechnology, the company focuses on improving healthcare outcomes through advanced cancer imaging applications.
Average Trading Volume: 3,570,118
Technical Sentiment Signal: Hold
Current Market Cap: A$14.63M
See more data about IBX stock on TipRanks’ Stock Analysis page.